PCSK9 Genotype (p.Arg46Leu)

About 2 to 3 percent of people of European ancestry carry a tiny spelling change in a gene called PCSK9 that gives them a measurable lifelong advantage. Their LDL cholesterol runs roughly 9 to 15 percent lower than non-carriers, and their risk of coronary heart disease is sharply reduced. This single DNA test tells you whether you were born with that biological head start, or whether you need to earn it through diet, exercise, and medication.

This is a one-time test that does not change over your life. The variant being checked is called R46L (formally p.Arg46Leu), a known loss-of-function change in the PCSK9 (proprotein convertase subtilisin/kexin type 9) gene. Knowing your status reframes how aggressively you should view your other cardiovascular numbers.

What This Variant Actually Does

PCSK9 is a protein your liver makes that destroys LDL receptors, the docking ports your liver uses to pull cholesterol out of your blood. Less PCSK9 activity means more docking ports, which means more cholesterol gets cleared. The R46L variant produces a slightly weaker version of PCSK9, so carriers naturally have lower LDL cholesterol from birth onward.

Because the effect is constant across decades, the protection adds up. A modest 10 to 15 percent reduction in LDL over a few years has a small impact, but the same reduction sustained across an entire life reshapes cardiovascular risk in a much larger way. That is the central insight behind testing for this variant.

Heart Disease Risk

Carriers of R46L have substantially lower risk of coronary heart disease across multiple large studies. Reported reductions range from about 17 percent in some analyses to nearly 47 percent in others, depending on the population and how the variant was studied. In healthy U.K. men, carriers had a 9 percent reduction in total cholesterol and a 15 percent reduction in LDL cholesterol, paired with notably lower coronary disease rates.

In dose terms, heterozygotes (one copy of R46L) showed LDL roughly 15.5 mg/dL lower, while homozygotes (two copies) showed LDL roughly 25.2 mg/dL lower than non-carriers. Whether you carry one copy or two changes how big the inherited cholesterol advantage actually is. Beyond LDL itself, NMR profiling has shown carriers also tend to have fewer VLDL and LDL particles overall, and lower activity of inflammatory phospholipases tied to vascular injury, suggesting the protection extends past a single cholesterol number. Carriers also tend to run modestly lower lipoprotein(a) in some Copenhagen analyses, though that effect is small and inconsistent across cohorts.

Stroke Risk

Despite the strong protection against coronary disease, R46L does not appear to lower the risk of ischemic stroke. A meta-analysis found essentially no link, with carriers having roughly the same stroke risk as non-carriers. Interestingly, this is one place where the genetics and the drug evidence diverge: randomized trials of PCSK9-inhibitor medication do reduce stroke risk, while the inherited variant does not. The discordance is a useful reminder that a lifelong genetic advantage and a few years of pharmacological treatment can act through somewhat different pathways.

Aortic Valve Disease

Carriers of R46L are also less likely to develop calcific aortic valve stenosis, the buildup of calcium on the heart's main outflow valve that eventually requires valve replacement. In a Copenhagen study of more than 100,000 people focused on R46L itself, carriers had odds of aortic stenosis about 36 percent lower than non-carriers (odds ratio 0.64). A broader analysis pooling several rare lipid variants found a smaller but still meaningful effect of about 23 percent. Either way, lifelong lower cholesterol appears to slow the calcification of the valve, not just the arteries.

Type 2 Diabetes Risk

There may be a flip side, but the evidence is mixed. Mendelian randomization studies using broader PCSK9 genetic scores have suggested the same variants that lower LDL through PCSK9 also raise type 2 diabetes risk modestly, with an odds ratio around 1.29 per 10 mg/dL of inherited LDL reduction. A 2024 meta-analysis specific to R46L found about a 9 percent higher diabetes risk in carriers.

However, several well-powered studies focused on R46L alone have found no significant link. A French cohort of 4,630 adults found no association between R46L and fasting glucose, insulin, HbA1c, or 9-year incident diabetes. The R46L-specific arm of the Ference NEJM analysis crossed the null. A 2025 multi-ancestry MR study found no diabetes signal in East Asian, South Asian, Hispanic, or European populations. The honest read is that R46L's effect on diabetes is, at most, small and inconsistent across populations.

A few small studies have also suggested R46L carriers carry slightly more abdominal or liver fat, but the largest analysis (over 339,000 people using a broader PCSK9 genetic score) found no association with BMI, waist circumference, or waist-to-hip ratio. So the body-composition concern, like the diabetes signal, is preliminary rather than settled.

Liver and Fatty Liver Disease

The liver story is unresolved. In a biopsy-based cohort of people at high risk for nonalcoholic fatty liver disease, R46L was associated with lower odds of fatty liver, NASH (nonalcoholic steatohepatitis), and severe fibrosis. A separate Italian study, though, found that R46L carriers had about twice the prevalence of hepatic steatosis on imaging, a finding echoed in PCSK9 knockout mice. The American Heart Association explicitly notes that data on PCSK9 inhibition and NAFLD remain insufficient to draw firm conclusions. What does look reassuring is that Mendelian randomization of common liver enzymes (ALT, AST, GGT, ALP) shows no signal of liver injury from low PCSK9 activity.

Putting the Tradeoffs in Context

Even taking the contested diabetes and liver signals at face value, the overall balance for R46L carriers is favorable. The cardiovascular protection is large and reproducible across many cohorts. Any diabetes or fatty liver effect, if real, is small and lifestyle-modifiable, while coronary disease is much harder to reverse once it has taken hold. The variant is best thought of as one inherited dial that has already been set in your favor on the cardiovascular axis, with weaker and less consistent effects elsewhere.

What This Test Is Not

This test reads your DNA at one specific spot in the PCSK9 gene. It does not measure circulating PCSK9 protein, LDL cholesterol, Lp(a), or any other blood-based marker. Two people with identical R46L status can have very different cholesterol numbers depending on diet, weight, other genes, and medication. Think of R46L as one inherited dial that has already been set, not the whole thermostat.

Why a Single Reading Is Enough

Unlike cholesterol or glucose, your PCSK9 R46L genotype is fixed at conception and stable for life. You do not need to retest it. There is no biological variability, no fasting requirement, no time-of-day issue. One accurate result is permanent information you can carry forward.

What does need ongoing tracking is the downstream picture: LDL cholesterol, ApoB, Lp(a), HbA1c, and liver markers. A favorable R46L result means your inherited LDL is probably a bit lower, but it does not free you from monitoring the rest of your cardiovascular and metabolic numbers over time. A non-carrier result does not mean disaster, it just means you do not have this particular built-in advantage and should be more deliberate about everything you can control.

What to Do With Your Result

If you carry the variant, treat the result as one favorable factor inside a larger risk picture. Continue to track LDL cholesterol or ApoB, blood pressure, HbA1c, and family history of heart disease. The variant lowers risk, but does not eliminate it, and lifestyle choices still matter. Given the small signal toward higher diabetes risk and slightly higher body fat in some carriers, paying attention to weight, fasting insulin, and HbA1c is reasonable.

If you do not carry the variant, nothing has changed about your biology compared to before testing. You simply do not have this specific inherited boost, which makes baseline lipid and cardiovascular monitoring more important. Pair this result with ApoB, Lp(a), and a standard lipid panel to get a full read on your atherosclerotic risk. If your LDL or ApoB looks high, talk with a lipidologist or preventive cardiologist about whether earlier, more aggressive treatment makes sense, especially if you also have a family history of premature heart disease.